AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.

Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.

Kura will see more combo data, while a new contender from Sumitomo emerges.

Reports of Arc-10's failure are greatly exaggerated, the company argues.

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

There’s little to distinguish the two HIF2α inhibitors in kidney cancer.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.